🚨Moderna's new mRNA flu vaccine reduced absolute influenza risk by 0.8% in trials. In the same trials, 6.4% of recipients suffered severe reactions, five times the rate of the standard flu shot, and five mFlusiva recipients died in the Phase 3 trial compared to one in the standard flu shot group. Cardiac events, including fatal cardiac arrest, were also recorded. @ICANdecide sent an urgent letter to FDA's advisory committee documenting every one of these concerns before the vote. The committee acknowledged them, then voted unanimously to recommend approval anyway, with a note that further studies should be conducted after the vaccine is already in use. America's most vulnerable seniors, the population for whom mFlusiva showed no statistically significant efficacy at all, will once again serve as the test group while regulators wait years to determine whether the product is causing harm. ICAN will be filing FOIA requests for the full clinical trial data if mFlusiva receives final approval from FDA Acting Commissioner Kyle Diamantas. Full article linked below 👇